Medication Monitor



Generic Name (Trade Name—Company)
Notes
May 20, 2011

Sunitinib

(Sutent—Pfizer)
Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors

Uses:

Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease

Sunitinib is also approved for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumor (GIST) after disease progression with imatinib (Gleevec—Novartis) or in those with GIST intolerant to imatinib. Data from the SUN 111 trial showed that patients with unresectable pancreatic NET treated with sunitinib had a clinically significant improvement in progression-free survival compared with placebo (10.2 mo vs. 5.4 mo). An objective response rate of 9.3% was also observed in the sunitinib group, while no objective response occurred in the placebo group. The recommended dose for pancreatic NET is 37.5 mg once daily without a scheduled off-treatment period.